Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Interchangeability, immunogenicity and biosimilars

Nature Biotechnology volume 30, pages 1186–1190 (2012)Cite this article

Subjects

For authorized biosimilars to achieve full acceptance in the marketplace, it is crucial that they are considered to be therapeutically equivalent and interchangeable with the brand reference product.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. European Commission. Off. J. Eur. Union L136, 34–57 (2004).

  2. Health, I.M.S. Shaping the Biosimilars Opportunity: a Global Perspective on the Evolving Biosimilars Landscape (IMS Health, New York, USA, 2011; accessed 11 April 2012). <http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf>

    Google Scholar 

  3. European Medicines Agency. Volume 9A of The Rules Governing Medicinal Products in the European Union. (EMA, London, 2008; accessed 2 August 2012). <http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf>

  4. European Commission. Off. J. Eur. Union L311, 67–267 (2001).

  5. European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (EMA, London, 2007; accessed 3 July 2012). <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003947.pdf>

  6. Casadevall, N. et al. N. Engl. J. Med. 346, 469–475 (2002).

    Article  CAS  Google Scholar 

  7. Gascon, P. et al. Ann. Oncol. 21, 1419–1429 (2010).

    Article  CAS  Google Scholar 

  8. European Medicines Agency. EPARs for Authorised Medicinal Products for Human Use (EMA, London; accessed 9 September 2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124

  9. Frau, S., Font Pous, M., Luppino, M.R. & Conforti, A. Eur. J. Clin. Pharmacol. 66, 785–790 (2010).

    Article  CAS  Google Scholar 

  10. Haag-Weber, M. et al. Clin. Nephrol. 77, 8–17 (2012).

    Article  CAS  Google Scholar 

  11. Seidl, A. et al. Pharm. Res. 29, 1454–1467 (2012).

    Article  CAS  Google Scholar 

  12. Jiang, Y. et al. J. Pharm. Sci. 98, 4695–4710 (2009).

    Article  CAS  Google Scholar 

  13. Praditpornsilpa, K. et al. Kidney Int. 80, 88–92 (2011).

    Article  CAS  Google Scholar 

  14. Peterson, G.M. Br. J. Clin. Pharmacol. 71, 966–967, author reply 968 (2011).

    Article  Google Scholar 

  15. Meredith, P.A. Curr. Med. Res. Opin. 25, 2179–2189 (2009).

    Article  CAS  Google Scholar 

  16. Walsh, G. Drug Discov. Today 15, 773–780 (2010).

    Article  CAS  Google Scholar 

  17. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues EMEA/CHMP/BMWP/42832/2005 (EMA, London, 2006; accessed 26 July 2012). <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf>

  18. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (EMA, London, 2006). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf

  19. Covic, A. et al. Nephrol. Dial. Transplant. 23, 3731–3737 (2008).

    Article  Google Scholar 

  20. Rovira, J., Espin, J., Garcia, L. & Olry de Labry, A. The Impact of Biosimilars' Entry in the EU Market (Andalusian School of Public Health, Spain, 2011).

    Google Scholar 

  21. Niederwieser, D. & Schmitz, S. Eur. J. Haematol. 86, 277–288 (2011).

    Article  CAS  Google Scholar 

  22. Minghetti, P., Rocco, P., Del Vecchio, L. & Locatelli, F. Nephron Clin. Pract. 117, c1–c7 (2011).

    Article  CAS  Google Scholar 

  23. Brinks, V. et al. Pharm. Res. 28, 386–393 (2011).

    Article  CAS  Google Scholar 

  24. Storring, P.L. et al. Br. J. Haematol. 100, 79–89 (1998).

    Article  CAS  Google Scholar 

  25. Schiestl, M. et al. Nat. Biotechnol. 29, 310–312 (2011).

    Article  CAS  Google Scholar 

  26. Vanrenterghem, Y. et al. Kidney Int. 62, 2167–2175 (2002).

    Article  CAS  Google Scholar 

  27. Dellanna, F. et al. Int. J. Clin. Pract. 65, 64–72 (2011).

    Article  CAS  Google Scholar 

  28. Ebbers, H.C., Muenzberg, M. & Schellekens, H. Exp. Opin. Biol. Ther. 12, 1473–1485 (2012).

    Article  CAS  Google Scholar 

  29. Duerden, M.G. & Hughes, D.A. Br. J. Clin. Pharmacol. 70, 335–341 (2010).

    Article  Google Scholar 

  30. Kresse, G.B. Eur. J. Pharm. Biopharm. 72, 479–486 (2009).

    Article  CAS  Google Scholar 

  31. Declerck, P.J. et al. Curr. Med. Res. Opin. 26, 1219–1229 (2010).

    Article  CAS  Google Scholar 

  32. Shankar, G., Pendley, C. & Stein, K.E. Nat. Biotechnol. 25, 555–561 (2007).

    Article  CAS  Google Scholar 

  33. Macdougall, I.C. et al. N. Engl. J. Med. 361, 1848–1855 (2009).

    Article  CAS  Google Scholar 

  34. European Medicines Agency. Scientific Guidance Documents on Biosimilar Medicines (EMA, London; accessed 4 September 2012) <http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac058002958c&jsenabled=true>

Download references

Author information

Authors and Affiliations

  1. Hans C. Ebbers is in the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.,

    Hans C Ebbers

  2. Stacy A. Crow and Arnold G. Vulto are in the Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands,

    Stacy A Crow & Arnold G Vulto

  3. Huub Schellekens is at the Copernicus Institute/Department of Innovation and Environmental Studies, and the Department of Pharmaceutics, UIPS, Utrecht University, Utrecht, The Netherlands.,

    Huub Schellekens

Authors
  1. Hans C Ebbers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stacy A Crow
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arnold G Vulto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huub Schellekens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans C Ebbers.

Ethics declarations

Competing interests

The authors declare no conflict of interest relevant to the subject matter or materials discussed in the manuscript. No funding was received for the preparation of this article. This study was performed in the context of the Escher project (T6-202), a project of the Dutch Top Institute Pharma. The division of Pharmacoepidemiology and Clinical Pharmacology, where H.C.E. is employed, has received unrestricted funding for pharmaco-epidemiological research from GlaxoSmithKline, the private-public funded Top Institute Pharma (http://www.tipharma.nl, includes co-funding from universities, government and industry), the Dutch Medicines Evaluation Board and the Dutch Ministry of Health. H.S. participated in meetings and publications sponsored by Amgen, Johnson & Johnson, Roche, Sandoz and Hospira. Part of his research is directly or indirectly sponsored by Roche, Amgen and Sandoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ebbers, H., Crow, S., Vulto, A. et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 30, 1186–1190 (2012). https://doi.org/10.1038/nbt.2438

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2438

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research